FDLI Insighter

FDLI’s Insighter is a periodic column that offers a fresh perspective on issues affecting the food and drug industry.

If you’re interested in writing an FDLI Insighter column, please contact
Michael Levin-Epstein, Editor-in-Chief, (202) 222-0897 or mdl@fdli.org.

2008

| April 10
Foods v. Drugs: Does FDAAA § 912 Redraw the Line?
> By Diane B. McColl and Ricardo Carvajal

| February 19
FDA Should Systematically Gather Basic Nanomaterial Information
> By John C. Monica, Jr.

| January 23
FDA Begins to Tackle Nanotech Challenge
> By Beryl Lieff Benderly

2007

| November 6
FDA Appoints Risk Communication Advisory Committee
> By Beryl Lieff Benderly

| September 25
Fixing FDA Imports: It’s Not Rocket Science
> By Benjamin L. England

| July 20
Final Dietary Supplement cGMP Rules Stretch FDA’s Records
Inspection Authority Beyond its Limits
> By John G. Moore, J.D., Ph.D.

| June 13
Rights and Responsibilities in Providing Unapproved Drug
to Dying Patients
> By James J. Kelly, President and CEO, FDLI

| March 24
New Laws Will Mean Fewer Drugs
> By Henry I. Miller

| Jan 22
FDA Primed to Help Dying Patients Gain Easier Access to
Unapproved Drugs
> By Beryl Lieff Benderly